2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Eukaryotic Initiation Factor (eIF)

Eukaryotic Initiation Factor (eIF)

Eukaryotic Initiation Factor (eIF)

Related Products

PDF 0.58 MB

Eukaryotic initiation factors (eIFs) are proteins involved in the initiation phase of eukaryotic translation. These proteins help stabilize the formation of the functional ribosome around the start codon and also provide regulatory mechanisms in translation initiation.

Eukaryotic initiation factor 2B (eIF2B) is a guanine nucleotide-exchange factor which mediates the exchange of GDP (bound to initiation factor eIF2) for GTP, thus regenerating the active [eIF2.GTP] complex that is required for peptide-chain initiation. The activity of eIF2B is a key control point for eukaryotic protein synthesis and is altered in response to viral infection, hormones, nutrients, growth factors and certain stresses.

Eukaryotic translation initiation factor 4E (eIF4E) is best known for its function in the initiation of protein synthesis on capped mRNAs in the cytoplasm. Eukaryotic initiation factor (elF) 4A functions as a subunit of the initiation factor complex elF4F, which mediates the binding of mRNA to the ribosome.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-145240
    eIF4E-IN-1
    		Inhibitor
    eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y).
    eIF4E-IN-1
  • HY-177074
    Comtifator
    		Modulator
    Comtifator (Example 77) is a modulator of the integrated stress response pathway. Comtifator can be studied in research for diseases associated with integrated stress response.
    Comtifator
  • HY-186186
    FD236
    		Inhibitor
    FD236, an eIF4A inhibitor, is the payload of DL149 (HY-183253).
    FD236
  • HY-183253
    DL149
    		Inhibitor
    DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors.
    DL149
  • HY-P10757
    DTX-P7
    		Activator
    DTX-P7 is a peptide-drug conjugate. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90.
    DTX-P7
  • HY-182360
    Cytisine-platinum(IV) prodrug-1
    Cytisine-Platinum(IV) Prodrug-1 is a Pt(IV) prodrug incorporating the natural compound Cytisine (HY-N0175) with antiproliferative activity against tumor cells. Cytisine-Platinum(IV) Prodrug-1 promotes calcium transfer across the IP3R1-GRP75-VDAC1 axis to drive mitochondrial calcium overload. Cytisine-Platinum(IV) Prodrug-1 initiates unfolded protein response via PERK, eIF2α, ATF4, and CHOP to modulate Bcl-2 and Bax, triggering apoptosis. Cytisine-Platinum(IV) Prodrug-1 induces mitochondrial dysfunction, ROS production, reduced ATP synthesis, DNA damage, and S-phase cell cycle arrest. Cytisine-Platinum(IV) Prodrug-1 activates the cGAS-STING pathway, reduces PD-L1 expression, drives immunogenic cell death. Cytisine-Platinum(IV) Prodrug-1 exhibits high physiological stability, efficient cellular accumulation, and enhanced platinum-DNA binding, and inhibits tumor growth in mouse models with reduced systemic toxicity. Cytisine-Platinum(IV) Prodrug-1 can be used for the research of lung cancer.
    Cytisine-platinum(IV) prodrug-1
  • HY-158198
    PRXS571
    		Modulator
    PRXS571 is a potent modulator of the neuronal integrated stress response (ISR) and can be used in neural-related research.
    PRXS571
  • HY-E70712
    EIF2AK4 Recombinant Human Active Protein Kinase
    EIF2AK4 Recombinant Human Active Protein Kinase belongs to a family of kinases that regulate angiogenesis in response to cellular stress. EIF2AK4 Recombinant Human Active Protein Kinase can be used for the study of pulmonary capillary hemangiomatosis (PCH).
    EIF2AK4 Recombinant Human Active Protein Kinase
  • HY-175877
    RAPT-37-Me
    		Modulator
    RAPT-37-Me is a GCN2-targeting agent with IC50 values of 0.002μM, ＞ 10 μM,4.40 μM and 1.31 μM for GCN2, PERK, HRl and PKR, respectively.
    RAPT-37-Me
  • HY-181406
    eIF2B activator-1
    		Activator
    eIF2B activator-1 (Compound 7a) is a eIF2B activator with a pEC50 value of 7.3. eIF2B activator-1 exhibits significant hERG inhibitory activity, with a pIC50 value of 5.7. eIF2B activator-1 can be used in research related to Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
    eIF2B activator-1
  • HY-155676
    eIF4E-IN-5
    		Inhibitor
    eIF4E-IN-5 (Compound 6n) is a eIF4E cell-permeable inhibitor. eIF4E-IN-5 can bind to capped mRNA to inhibit cap-dependent translation.
    eIF4E-IN-5
  • HY-164026
    ISR modulator-1
    		Modulator
    ISR modulator-1 (Compound 212) is a modulator for integrated stress response pathway (ISR)
    ISR modulator-1
  • HY-112654A
    GCN2iB acetate
    		Inhibitor
    GCN2iB acetate is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB acetate inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB acetate enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB acetate increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB acetate can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.
    GCN2iB acetate
  • HY-181627
    ETC-501
    		Modulator
    ETC-501 is a blood-brain barrier-permeable, orally active, and selective MNK1/MNK2 inhibitor, with an IC50 of 0.033 μM against MNK1 and 0.111 μM against MNK2. ETC-501 inhibits glioblastoma cell proliferation, impairs DNA damage repair function, delays cell cycle progression, and suppresses ribosome biogenesis. ETC-501 enhances Temozolomide (HY-17364)-induced cellular senescence, attenuates the senescence-associated secretory phenotype, and increases cellular sensitivity to Navitoclax (HY-10087). ETC-501 is applicable to research related to glioblastoma.
    ETC-501
  • HY-182046
    HD202A
    		Inhibitor
    HD202A is an orally active, selective dual inhibitor of MNK1/MNK2 (with IC50 values of 6.09 nM and 8.06 nM, and Kd values of 1.913 μM and 5.244 μM, respectively) that inhibits the MNK-eIF4E signaling pathway. By downregulating perilipin 2 and SCD1, while upregulating adipose triglyceride lipase and PPARγ coactivator 1α, HD202A enhances mitochondrial fatty acid oxidation and redox homeostasis. HD202A effectively suppresses body weight gain, hepatic lipid accumulation and elevation of serum lipids, significantly improves glucose tolerance and insulin sensitivity of the organism, and ameliorates inflammatory features. With these comprehensive pharmacological activities, HD202A exhibits great application potential in studies of metabolic dysfunction-associated steatotic liver disease.
    HD202A
  • HY-19356B
    (+)-Rocaglamide
    		Inhibitor
    (+)-Rocaglamide is the dextrorotatory enantiomer of Rocaglamide (HY-19356). Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of 50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.
    (+)-Rocaglamide
  • HY-176843
    eIF4A-IN-2
    		Inhibitor
    eIF4A-IN-2 (Compound 93) is an Eukaryotic translation initiation factor 4A (eIF4A) inhibitor. eIF4A-IN-2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
    eIF4A-IN-2
  • HY-176842
    eIF4A-IN-1
    		Inhibitor
    eIF4A-IN-1 (Compound 79) is an eIF4A inhibitor that inhibits protein translation. eIF4A-IN-1 canb be used in gastric cancer research.
    eIF4A-IN-1
  • HY-182939
    MNK1/2-IN-10
    		Inhibitor
    MNK1/2-IN-10 is an orally active, selective MNK1/MNK2 inhibitor, with an IC50 of 10.84 nM for MNK1 and an IC50 of 12.81 nM for MNK2. MNK1/2-IN-10 inhibits eIF4E phosphorylation, the NF-κB signaling pathway, macrophage polarization, oxidative stress and the production of pro-inflammatory cytokines. MNK1/2-IN-10 alleviates kidney and spleen damage in LPS (HY-D1056)-induced inflammatory mouse models. Anti-inflammatory agent 115 is applicable for research related to acute inflammation.
    MNK1/2-IN-10
  • HY-183703
    ISR activator-4
    		Modulator
    ISR activator-4 is an eIF2B modulator and integrated stress response (ISR) activator with a human eIF2B EC50 of 2.2 μM. ISR activator-4 stabilises the inactive I-state of eIF2B, favours formation of the inhibitory eIF2B-eIF2(αP) complex, and attenuates eIF2B's guanine nucleotide exchange factor activity. ISR activator-4 can be used for the research of cancer, neurologic and metabolic disorders.
    ISR activator-4
Cat. No. Product Name / Synonyms Application Reactivity